title: Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis.
abstract: BACKGROUND
  Ciclesonide is an intranasal corticosteroid approved for the treatment of allergic rhinitis (AR).
  
  
  OBJECTIVE
  To evaluate the time to onset of action of ciclesonide, 200 microg/d, in patients with seasonal AR (SAR).
  
  
  METHODS
  In a double-blind, randomized, placebo-controlled study conducted in an environmental exposure chamber, 509 adults with at least a 2-year history of SAR completed 1 to 5 priming sessions of ragweed pollen exposure (mean [SD] of 3,500 [500] grains/m3). Patients with successful priming visits (defined as patient-assessed instantaneous total nasal symptom scores [TNSSs] > or =6 and rhinorrhea or nasal congestion scores -2) received a single dose of intranasal ciclesonide, 200 microg (n = 255), or placebo (n = 254). The difference in the change from baseline in TNSSs between the ciclesonide and placebo groups was measured hourly 1 to 12 hours after study drug administration.
  
  
  RESULTS
  At hour 6, the mean treatment difference in TNSSs between ciclesonide and placebo was 0.53 (95% confidence interval, 0.03-1.03; P = .02). Significant treatment differences in favor of ciclesonide were also observed at 2 additional time points: hour 10 (P = .01) and hour 12 (P = .008).
  
  
  CONCLUSIONS
  These results confirm that intranasal ciclesonide, 200 microg/d, has an onset of action of 6 hours in patients with SAR.
authors.affiliation: Allied Research International-Cetero Research, Mississauga, Ontario, Canada. PCouroux@allied-research.com
authors.forename: Peter
authors.initials: P
authors.lastname: Couroux
authors.forename: Sudeesha
authors.initials: S
authors.lastname: Kunjibettu
authors.forename: Nancy
authors.initials: N
authors.lastname: Hall
authors.forename: Mark A
authors.initials: MA
authors.lastname: Wingertzahn
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000368:Aged; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011282:Pregnenediones / Q000008:administration & dosage*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology; D013997:Time Factors; D055815:Young Adult
chemical_list: D018926:Anti-Allergic Agents; D011282:Pregnenediones; C120481:ciclesonide